In the following sections, we review the clinical studies that have been published to date and their main findings in relation to the impact that myostatin levels have on RA disease, as well as what the authors propose, based on their results, to improve the quality of care for patients with RA. This evidence concerns the gene MSTN and rheumatoid arthritis.